| 臺大學術典藏 |
2020-12-02T02:34:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2020-11-27T08:14:24Z |
Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma
|
Hsiao S.-M.;Chen C.-A.;Hsu C.;Lin H.-H.;Chang-Yao Hsieh;Wei L.-H.; Hsiao S.-M.; Chen C.-A.; Hsu C.; Lin H.-H.; CHANG-YAO HSIEH; Wei L.-H. |
| 臺大學術典藏 |
2020-11-19T03:43:04Z |
HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity
|
Huang C.-L.; Hsu H.-C.; PO-HUANG LEE; Wang S.-J.; Cheng A.-L.; Hsu C.; Hsu C.;Huang C.-L.;Hsu H.-C.;Po-Huang Lee;Wang S.-J.;Cheng A.-L. |
| 臺大學術典藏 |
2020-11-19T03:42:56Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Hsu C.;Chen C.-N.;Chen L.-T.;Wu C.-Y.;Yang P.-M.;Lai M.-Y.;Po-Huang Lee;Cheng A.-L.; Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Yang P.-M.; Lai M.-Y.; PO-HUANG LEE; Cheng A.-L. |
| 臺大學術典藏 |
2020-11-19T03:19:32Z |
Lc3 over-expression improves survival and attenuates lung injury through increasing autophagosomal clearance in septic mice
|
Lo S.; Yuan S.-S.F.; Hsu C.; Cheng Y.-J.; Chang Y.-F.; Hsueh H.-W.; PO-HUANG LEE; Hsieh Y.-C. |
| 臺大學術典藏 |
2020-11-11T08:19:58Z |
Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data
|
Campbell B.C.V.; Ma H.; Ringleb P.A.; Parsons M.W.; Churilov L.; Bendszus M.; Levi C.R.; Hsu C.; Kleinig T.J.; Fatar M.; Leys D.; Molina C.; Wijeratne T.; Curtze S.; Dewey H.M.; Barber P.A.; Butcher K.S.; De Silva D.A.; Bladin C.F.; Yassi N.; Pfaff J.A.R.; Sharma G.; Bivard A.; Desmond P.M.; Schwab S.; Schellinger P.D.; Yan B.; Mitchell P.J.; Serena J.; Toni D.; Thijs V.; Hacke W.; Davis S.M.; Donnan G.A.; Donnan G.A.; Davis S.M.; Parsons M.W.; Mitchell P.J.; Desmond P.M.; Oxley T.; Wu T.Y.; Shah D.; Zhao H.; Rodrigues E.; Salvaris P.; Alemseged F.; Ng F.; Williams C.; Ng J.-L.; Tu H.T.-H.; McDonald A.; Jackson D.; Tsoleridis J.; McCoy R.; Pesavento L.; Weir L.; Kleinig T.J.; Patel S.; Harvey J.; Mahadevan J.; Cheong E.; Balabanski A.; Waters M.; Drew R.; Cranefield J.; Mackey E.; Celestino S.; Low E.; Dewey H.M.; Bladin C.F.; Loh P.S.; Choi P.M.; Coote S.; Frost T.; Hogan K.; Ding C.; McModie S.; Zhang W.W.; Kyndt C.; Moore A.; Ross Z.; Liu J.; Miteff F.; Levi C.R.; Ang T.; Spratt N.; Garcia-Esperon C.; Kaauwai L.; Phan T.G.; Ly J.; Singhal S.; Clissold B.; Wong K.; Krause M.; Day S.; Sturm J.; O'Brian B.; Grimley R.; Simpson M.; Lee-Archer M.; Brodtmann A.; Coulton B.; Young D.; Wong A.A.; Muller C.; Field D.K.; Vallat W.; Maxwell V.; Bailey P.; Sabet A.; Mishra S.; Tan M.; George K.; Barber P.A.; Zhao L.; Meretoja A.; Tatlisumak T.; Sibolt G.; Tiainen M.; Koivu M.; Aarnio K.; Virta J.; Kasari O.; Eirola S.; Sun M.C.; Chen T.C.; Chuang C.S.; Chen Y.Y.; Lin C.M.; Ho S.C.; Hsiao P.M.; Tsai C.H.; Huang W.S.; Yang Y.W.; Huang H.Y.; Wang W.C.; Liu C.H.; Lu M.K.; Lu C.H.; Kung W.L.; Jiang S.K.; Wu Y.H.; Huang S.C.; Tseng C.H.; Tseng L.T.; Guo Y.C.; Lin D.; Hsu C.T.; Kuan C.W.; Hsu J.P.; Tsai H.T.; Suzuki M.; Sun Y.; Chen H.F.; Lu C.J.; Lin C.H.; Huang C.C.; Chu H.J.; Lee C.Y.; Chang W.H.; Lo Y.C.; Hsu Y.T.; CHIH-HAO CHEN; Sung P.S.; Ysai C.L.; Jeng J.S.; Tang S.C.; Tsai L.K.; Yeh S.J.; Lee Y.C.; Wang Y.T.; Chung T.C.; Hu C.J.; Chan L.; Chiou Y.W.; Lien L.M.; Yeh H.L.; Yeh J.H.; Chen W.H.; Lau C.L.; Chang A.; Lee I.Y.; Huang M.Y.; Lee J.T.; Peng G.S.; Lim J.C.; Hsu Y.D.; Lin C.C.; Cheng C.A.; Yen C.H.; Yang F.C.; Hsu C.H.; Sung Y.F.; Tsai C.K.; Tsai C.L.; Lee A.; Hankey G.; Blacker D.; Gerraty R.; Chen C.-I.; Hsu C.-S.; Cowley E.; Sallaberger M.; Snow B.; Kolbe J.; Stark R.; King J.; Macdonnell R.; Attia J.; D'Este C.; Bernhardt J.; Carey L.; Cadilhac D.; Anderson C.; Howells D.; Barber A.; Connelly A.; Macleod M.; O'Collins V.; Wilson W.; Macaulay L.; Bluhmki E.; Eschenfelder C.; Ringleb P.; Wahlgren N.; Wardlaw J.; Oppenheim C.; Lees K.R.; Kaste M.; von Kummer R.; Chatellier G.; Laage R.; Nu?ez X.; Ehrenkrona C.; Svenson A.-S.; Cove L.; Niederkorn K.; Gruber F.; Kapeller P.; Mikulik R.; Mas J.-L.; Berrouschot J.; Sobesky J.; K?hrmann M.; Steiner T.; Kessler C.; Dziewas R.; Poli S.; Althaus-Knaurer K.; Bovi P.; Rodriguez A.L.; Arenillas J.F.; Muir K.; Veltkamp R.; Dixit A.; Muddegowda G.; Kala L.; De Silva D.A.; Butcher K.S.; Byrnes G.; Peeters A.; Chalk J.B.; Fink J.N.; Kimber T.E.; Schultz D.; Hand P.J.; Frayne J.; Tress B.M.; McNeil J.; Burns R.; Johnston C.; Williams M.; EXTEND, ECASS-4; EPITHET Investigators |
| 臺大學術典藏 |
2020-11-02T02:04:37Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; MING-SHIANG WU; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2020-10-23T03:49:06Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu E.-T.; Hwu W.-L.; Chien Y.-H.; Hsu C.; Chen T.-F.; Chen N.-Q.; Chou H.-C.; PO-NIEN TSAO; Fan P.-C.; Tsai I.-J.; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2020-10-20T01:45:47Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
TAI-CHUNG HUANG; Ko B.-S.; Tang J.-L.; Hsu C.; Chen C.-Y.; Tsay W.; Huang S.-Y.; Yao M.; Chen Y.-C.; Shen M.-C.; Wang C.-H.; Tien H.-F. |
| 臺大學術典藏 |
2020-09-30T08:49:47Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.; YEN-WEN WU; Liu K.-L.; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; Tzen K.-Y.; Wang H.-P. |
| 臺大學術典藏 |
2020-09-29T06:53:04Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Kuo S.-H.; Cheng A.-L.; Tien Y.-W.; Yeh K.-H.; Hsu C.-H.; Hsu C.; Wu H.; Guo J.-C.; TING-CHUN KUO; Yang S.-H. |
| 臺大學術典藏 |
2020-09-29T01:47:44Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Yeh K.-H.; Cheng A.-L.; Yang J.C.-H.; Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; YEE-CHUN CHEN; Hu F.-C. |
| 臺大學術典藏 |
2020-09-23T07:36:15Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Mei-Fang Cheng;Wu Y.-W.;Liu K.-L.;Yen R.-F.;Wu Y.-M.;Hsu C.;Chang Y.-T.;Tzen K.-Y.;Wang H.-P.; MEI-FANG CHENG; Wu Y.-W.; Liu K.-L.; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; Tzen K.-Y.; Wang H.-P. |
| 臺大學術典藏 |
2020-09-23T06:22:40Z |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
|
Hsu C.; Hong R.-L.; Tzen C.-Y.; Jeng Y.-M.; RUOH-FANG YEN; Lin C.-H.; Lin C.-H.;Ruoh-Fang Yen;Jeng Y.-M.;Tzen C.-Y.;Hsu C.;Hong R.-L. |
| 臺大學術典藏 |
2020-09-23T06:22:31Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.; Wu Y.-W.; Liu K.-L.; RUOH-FANG YEN; Wu Y.-M.; Hsu C.; Chang Y.-T.; Tzen K.-Y.; Wang H.-P. |
| 臺大學術典藏 |
2020-09-22T07:39:54Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Chao-Yu Hsu ;Shen Y.-C. ;Yu C.-W. ;Hsu C. ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; CHAO-YU HSU; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-09-22T07:39:51Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Shih T.T.-F.; Cheng A.-L.; Hsu C.-H.; Hsu C.; Liang P.-C.; Chen B.-B.; CHAO-YU HSU; Yu C.-W. |
| 臺大學術典藏 |
2020-09-22T07:39:50Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Chao-Yu Hsu;Yu C.-W.;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; CHAO-YU HSU; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-14T03:15:33Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; I-LUN SHIH; Wu C.-H.; Hsu C.; Chen C.-H.; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2020-08-14T03:15:30Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; I-LUN SHIH; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-08-13T06:34:06Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.; Yang C.-H.; Yu C.-J.; JIN-YUAN SHIH; Hsu C.; Yang P.-C.; Su W.-P.;Yang C.-H.;Yu C.-J.;Jin-Yuan Shih;Hsu C.;Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:34:05Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Yang P.-C.; Yu C.-J.; Yang T.-Y.; Yang C.-H.; JIN-YUAN SHIH; Chen K.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Yang C.-H.; Yang P.-C.; Huang T.-C.; Lin C.-C.; Yu C.-J.; Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-12T06:35:54Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
CHONG-JEN YU; Hsu C.; Cheng A.-L.; Yang P.-C.; Kuo S.-H.; Yang C.-H.; Kuo S.-H.;Yang C.-H.;Chong-Jen Yu;Hsu C.;Cheng A.-L.;Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T06:35:50Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Chong-Jen Yu;Shih J.-Y.;Hsu C.;Yang P.-C.; Su W.-P.; Yang C.-H.; CHONG-JEN YU; Shih J.-Y.; Hsu C.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T06:35:41Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
Chen J.-P.;Lo Y.;Chong-Jen Yu;Hsu C.;Shih J.-Y.;Yang C.-H.; Chen J.-P.; Lo Y.; CHONG-JEN YU; Hsu C.; Shih J.-Y.; Yang C.-H. |
| 臺大學術典藏 |
2020-08-12T06:35:40Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.;Hsu C.;Chang Y.-C.;Chong-Jen Yu;Hsu C.-H.;Lin C.-C.;Cheng A.-L.;Yang P.-C.;Yang C.-H.; Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2020-08-12T02:42:39Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Bang-Bin Chen;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; BANG-BIN CHEN; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-12T02:42:37Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Chao Y.; Hsu C.; Lee R.-C.; Lin Z.-Z.; BANG-BIN CHEN; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lin Z.-Z.;Bang-Bin Chen;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C. |
| 臺大學術典藏 |
2020-08-11T08:36:58Z |
Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: A preliminary result
|
PO-CHIN LIANG; Ch'ang H.-J.; Hsu C.; Tseng S.S.; Shih T.T.F.; Wu Liu T. |
| 臺大學術典藏 |
2020-08-11T08:36:56Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; Hsu C.; PO-CHIN LIANG; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2020-08-11T08:36:51Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-11T08:36:48Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; Chen C.-H.; Shih T.T.-F.; PO-CHIN LIANG; Liu K.-L. |
| 臺大學術典藏 |
2020-08-11T08:36:46Z |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
PO-CHIN LIANG; Ch’ang H.-J.; Hsu C.; Chen L.-T.; Shih T.T.F.; Liu T.W. |
| 臺大學術典藏 |
2020-08-11T08:36:45Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; PO-CHIN LIANG; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-11T08:36:42Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Po-Chin Liang;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Huo T.-I.; Liao L.-Y.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Lu S.-N. |
| 臺大學術典藏 |
2020-08-07T02:32:19Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; CHIH-HORNG WU; Hsu C.; Chen C.-H.; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2020-08-06T07:51:50Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Liang P.-C.; Liu K.-L.; TIFFANY TING-FANG SHIH; Chen C.-H.; Hsu C.; Wu C.-H.; Chen B.-B.; Shih I.-L. |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
TIFFANY TING-FANG SHIH; Liu T.W.; Chen L.-T.; Hsu C.; Liang P.-C.; Ch’ang H.-J. |
| 臺大學術典藏 |
2020-08-06T07:51:46Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2020-08-06T07:51:44Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH; Hsu C.-Y.; Chen B.-B. |
| 臺大學術典藏 |
2020-07-10T08:16:43Z |
Using standardised measures of health-related quality of life: Critical issues for users and developers
|
Kind, P.;Hsu, C.;Wang, J.-D.;Yao, G.;Tang, J.-L.; Kind, P.; Hsu, C.; Wang, J.-D.; Yao, G.; Tang, J.-L.; KAI-PING GRACE YAO |
| 臺大學術典藏 |
2020-07-09T02:57:04Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Hsu C.-Y. ;Shen Y.-C. ;Chih-Wei Yu ;Hsu C. ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; CHIH-WEI YU; Hsu C.; Hu F.-C. |
| 臺大學術典藏 |
2020-07-09T02:57:03Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
CHIH-WEI YU; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; Cheng A.-L.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; Hsu C. |
| 臺大學術典藏 |
2020-07-09T02:57:02Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; CHIH-WEI YU; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-09T02:57:01Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Hsu C.-Y.;Chih-Wei Yu;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; CHIH-WEI YU; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-03T08:45:47Z |
Induction of DNA damage-inducible gene GADD45�] contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Chen K.-F; Yu S.-L; Da-Liang Ou;Shen Y.-C;Yu S.-L;Chen K.-F;Yeh P.-Y;Fan H.-H;Feng W.-C;Wang C.-T;Lin L.-I;Hsu C;Cheng A.-L.; DA-LIANG OU; Shen Y.-C; Yeh P.-Y; Fan H.-H; Feng W.-C; Wang C.-T; Lin L.-I; Hsu C; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-03T08:45:44Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Feng Z.-R; Liou J.-Y; Fan H.-H; Lee B.-S; Hsu C; Cheng A.-L.Ann-Lii; Lin L.-I; Shyue S.-K; Da-Liang Ou;Shyue S.-K;Lin L.-I;Feng Z.-R;Liou J.-Y;Fan H.-H;Lee B.-S;Hsu C;Cheng A.-L.Ann-Lii; DA-LIANG OU |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy
|
Lin Y.-Z;Da-Liang Ou;Chang H.-Y;Lin W.-Y;Hsu C;Chang P.-L.; Lin Y.-Z; DA-LIANG OU; Chang H.-Y; Lin W.-Y; Hsu C; Chang P.-L. |
